BridgeMD
New treatment option for Hearing Loss
Official title Evaluating an Audiology Text-Message Protocol to Support Hearing Aid Use in NHS Adult Audiology Patients
ClinicalTrials.gov ID: NCT07146607
What this study is testing
- What it's testing
- Over 18 million adults in the United Kingdom have significant hearing loss, linked to isolation, depression and comorbidities. Hearing aids are the main management option yet are frequently unused (\~23%) or used irregularly (\<40%), wasting NHS resources and reducing quality-of-life gains.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- WP1: Pilot Feasibility Study (n=60, 30 per group intervention/control (treatment as usual)) Aged ≥18 years (no upper age limit)
- Prescribed their first NHS acoustic hearing aid(s) for the primary concern of hearing loss
- Able and willing to provide informed consent
- Not currently participating in similar research
- Access to a mobile device (This is not required to be a smart phone device)
You likely can't join if
- Registered on a pre-existing Florence text-messaging protocol.
- Unable to read/understand English WP2: Nested Process Evaluation (minimum n=10 patients, n=2 clinicians) Inclusion criteria (patients)
- Aged ≥18 years (no upper age limit)
- Prescribed their first NHS acoustic hearing aid(s) for the primary concern of hearing loss
- Able and willing to provide informed consent Exclusion criteria (patients)
- Registered on a pre-existing Florence text-messaging protocol.
See the full eligibility criteria
- WP1: Pilot Feasibility Study (n=60, 30 per group intervention/control (treatment as usual)) Aged ≥18 years (no upper age limit)
- Prescribed their first NHS acoustic hearing aid(s) for the primary concern of hearing loss
- Able and willing to provide informed consent
- Not currently participating in similar research
- Access to a mobile device (This is not required to be a smart phone device)
- Registered on a pre-existing Florence text-messaging protocol.
- Unable to read/understand English WP2: Nested Process Evaluation (minimum n=10 patients, n=2 clinicians) Inclusion criteria (patients)
- Aged ≥18 years (no upper age limit)
- Prescribed their first NHS acoustic hearing aid(s) for the primary concern of hearing loss
- Able and willing to provide informed consent Exclusion criteria (patients)
- Registered on a pre-existing Florence text-messaging protocol.
- Unable to read/understand English Inclusion criteria (clinicians)
- Aged ≥18 years (no upper age limit)
- Able and willing to provide informed consent Exclusion criteria (clinicians)
- Not meeting criteria for inclusion
The study team makes the final eligibility decision.
Where it's taking place
- Nottingham, Nottinghamshire, United Kingdom
- Sunderland, United Kingdom
- Wigan, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nottingham, Nottinghamshire, United Kingdom; Sunderland, United Kingdom; Wigan, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.